Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis
Siebert S, Coates L, Schett G, Raychaudhuri S, Chen W, Gao S, Seridi L, Chakravarty S, Shawi M, Lavie F, Sharaf M, Zimmermann M, Kollmeier A, Xu X, Rahman P, Mease P, Deodhar A. Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis. Arthritis & Rheumatology 2024, 76: 894-904. PMID: 38253404, DOI: 10.1002/art.42803.Peer-Reviewed Original ResearchBD-2 levelsTNFi-IRIL-23 signalingIL-22Clinical responseIL-17AInadequate response to tumor necrosis factor inhibitorsResponse to tumor necrosis factor inhibitorsTumor necrosis factor inhibitorsAmerican College of Rheumatology criteriaBiomarker levelsTNFi-IR patientsBD-2Serum biomarker levelsC-reactive proteinBaseline biomarker levelsActive PsAFactor inhibitorsPsA patientsWeek-24ACR20 respondersGuselkumabIL-17FRheumatology criteriaPharmacodynamic effects